The N-formyl peptide receptors and the anaphylatoxin C5a receptors: An overview

Biochimie

Volumn 89, Issue 9, 2007, Pages 1089-1106

  Rabiet, Marie Josèphe ^a   Huet, Emilie ^a   Boulay, François ^a  

^a CEA GRENOBLE   (France)

Author keywords

Anaphylatoxin; Chemoattractant receptors; Internalization; N formyl peptide; Phosphorylation; Signal transduction

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; FORMYLPEPTIDE RECEPTOR;

CELL FATE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HOST RESISTANCE; INTERNALIZATION; LEUKOCYTE ACTIVATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OLIGOMERIZATION; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, FORMYL PEPTIDE; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS);

EID: 34547899163     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.02.015     Document Type: Review

References (208)

1. Marasco W.A., Phan S.H., Krutzsch H., Showell H.J., Feltner D.E., Nairn R., Becker E.L., and Ward P.A. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J. Biol. Chem. 259 (1984) 5430-5439
2. Schiffmann E., Showell H.V., Corcoran B.A., Ward P.A., Smith E., and Becker E.L. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J. Immunol. 114 (1975) 1831-1837
3. Carp H. Mitochondrial N-formylmethionyl protein as chemoattractants for neutrophils. J. Exp. Med. 155 (1982) 264-275
4. Ye R., and Boulay F. Structure and function of leukocyte chemoattractant receptors. Adv. Pharmacol. 39 (1997) 221-290
5. Showell H.J., Freer R.J., Zigmond S.H., Schiffmann E., Aswanikumar S., Corcoran B., and Becker E.L. The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal enzyme secretion for neutrophils. J. Exp. Med. 143 (1976) 1155-1169
6. Boulay F., Tardif M., Brouchon L., and Vignais P. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 29 (1990) 11123-11133
7. Boulay F., Tardif M., Brouchon L., and Vignais P. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun. 168 (1990) 1103-1109
8. Bao L., Gerard N.P., Eddy Jr. R., Shows T.B., and Gerard C. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. Genomics 13 (1992) 437-440
9. Murphy P.M., Ozcelik T., Kenney R.T., Tiffany H.L., McDermott D., and Francke U. A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 267 (1992) 7637-7643
10. Ye R.D., Cavanagh S.L., Quehenberger O., Prossnitz E.R., and Cochrane C.G. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem. Biophys. Res. Commun. 184 (1992) 582-589
11. Fiore S., Maddox J.F., Perez H.D., and Serhan C.N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180 (1994) 253-260
12. Chiang N., Serhan C.N., Dahlen S.E., Drazen J.M., Hay D.W., Rovati G.E., Shimizu T., Yokomizo T., and Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58 (2006) 463-487
13. Fu H., Karlsson J., Bylund J., Movitz C., Karlsson A., and Dahlgren C. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukoc. Biol. 79 (2006) 247-256
14. Sahagun-Ruiz A., Colla J.S., Juhn J., Gao J.L., Murphy P.M., and McDermott D.H. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun. 2 (2001) 335-342
15. Zhang Y., Syed R., Uygar C., Pallos D., Gorry M.C., Firatli E., Cortelli J.R., VanDyke T.E., Hart P.S., Feingold E., and Hart T.C. Evaluation of human leukocyte N-formylpeptide receptor (FPR1) SNPs in aggressive periodontitis patients. Genes Immun. 4 (2003) 22-29
16. Wenzel-Seifert K., and Seifert R. Functional differences between human formyl peptide receptor isoforms 26, 98, and G6. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003) 509-515
17. Betten A., Bylund J., Cristophe T., Boulay F., Romero A., Hellstrand K., and Dahlgren C. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J. Clin. Invest. 108 (2001) 1221-1228
18. 2 specifically activates neutrophils through FPRL1/LXA4R and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276 (2001) 21585-21593
19. Migeotte I., Riboldi E., Franssen J.D., Gregoire F., Loison C., Wittamer V., Detheux M., Robberecht P., Costagliola S., Vassart G., Sozzani S., Parmentier M., and Communi D. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J. Exp. Med. 201 (2005) 83-93
20. Migeotte I., Communi D., and Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17 (2006) 501-519
21. Freer R.J., Day A.R., Radding J.A., Schiffmann E., Aswanikumar S., Showell H.J., and Becker E.L. Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry 19 (1980) 2404-2410
22. Derian C.K., Solomon H.F., Higgins III J.D., Beblavy M.J., Santulli R.J., Bridger G.J., Pike M.C., Kroon D.J., and Fischman A.J. Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues. Biochemistry 35 (1996) 1265-1269
23. Wenzel-Seifert K., and Seifert R. Cyclosporin H is a potent and selective formylpeptide receptor antagonist. J. Immunol. 150 (1993) 4591-4599
24. Wenzel-Seifert K., Hurt C.M., and Seifert R. High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273 (1998) 24181-24189
25. Mills J.S. Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor. Biochim. Biophys. Acta 1762 (2006) 693-703
26. de Haas C.J., Veldkamp K.E., Peschel A., Weerkamp F., Van Wamel W.J., Heezius E.C., Poppelier M.J., Van Kessel K.P., and van Strijp J.A. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199 (2004) 687-695
27. Prat C., Bestebroer J., de Haas C.J., van Strijp J.A., and van Kessel K.P. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 177 (2006) 8017-8026
28. Edwards B.S., Bologa C., Young S.M., Balakin K.V., Prossnitz E.R., Savchuck N.P., Sklar L.A., and Oprea T.I. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol. Pharmacol. 68 (2005) 1301-1310
29. Bae Y.S., Lee H.Y., Jo E.J., Kim J.I., Kang H.K., Ye R.D., Kwak J.Y., and Ryu S.H. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol. 173 (2004) 607-614
30. Cunningham C.C., Vegners R., Bucki R., Funaki M., Korde N., Hartwig J.H., Stossel T.P., and Janmey P.A. Cell permeant polyphosphoinositide-binding peptides that block cell motility and actin assembly. J. Biol. Chem. 276 (2001) 43390-43399
31. Fu H., Bjorkman L., Janmey P., Karlsson A., Karlsson J., Movitz C., and Dahlgren C. The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol. 5 (2004) 50-62
32. Baek S.H., Seo J.K., Chae C.-B., Suh P.-G., and Ryu S.H. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocytes cell lines from peptide libraries. J. Biol. Chem. 271 (1996) 8170-8175
33. Seo J.K., Choi S.-Y., Kim Y., Baek S.H., Kim K.-T., Chae C.-B., Lambeth J.D., Suh P.-G., and Ryu S.H. A peptide with unique receptor specificity. J. Immunol. 158 (1997) 1895-1901
34. Dahlgren C., Christophe T., Boulay F., Madianos P., Rabiet M.-J., and Karlson A. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-dMet activates neutrophils preferentially through the lipoxin A4 receptor. Blood 95 (2000) 1810-1818
35. Le Y., Gong W., Li B., Dunlop N.M., Shen W., Su S.B., Ye R.D., and Wang J.M. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163 (1999) 6777-6784
36. Klein C., Paul J.I., Sauve K., Schmidt M.M., Arcangeli L., Ransom J., Trueheart J., Manfredi J.P., Broach J.R., and Murphy A.J. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 16 (1998) 1334-1337
37. Le Y., Jiang S., Hu J., Gong W., Su S., Dunlop N.M., Shen W., Li B., and Ming Wang J. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. Clin. Immunol. 96 (2000) 236-242
38. Su S.B., Gong W.H., Gao J.L., Shen W.P., Grimm M.C., Deng X., Murphy P.M., Oppenheim J.J., and Wang J.M. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93 (1999) 3885-3892
39. Deng X., Ueda H., Su S.B., Gong W., Dunlop N.M., Gao J.-L., Murphy P.M., and Wang J.M. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94 (1999) 1165-1173
40. Shen W., Proost P., Li B., Gong W., Le Y., Sargeant R., Murphy P.M., Van Damme J., and Wang J.B. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell response to selected chemokines. Biochem. Biophys. Res. Commun. 272 (2000) 276-283
41. Rabiet M.J., Huet E., and Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35 (2005) 2486-2495
42. Bylund J., Christophe T., Boulay F., Nystrom T., Karlsson A., and Dahlgren C. Proinflammatory activity of a cecropin-like antibacterial peptide from Helicobacter pylori. Antimicrob. Agents Chemother. 45 (2001) 1700-1704
43. Bellner L., Thoren F., Nygren E., Liljeqvist J.A., Karlsson A., and Eriksson K. A proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, monocyte, and NK cell functions. J. Immunol. 174 (2005) 2235-2241
44. Su S.B., Gong W., Gao J.-L., Shen W., Murphy P.M., Oppenheim J.J., and Wang J.M. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189 (1999) 395-402
45. Le Y., Gong W., Tiffany H.L., Tumanov A., Nedospasov S., Shen W., Dunlop N.M., Gao J.L., Murphy P.M., Oppenheim J.J., and Wang J.M. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci. 21 (2001) 1-5
46. Iribarren P., Zhou Y., Hu J., Le Y., and Wang J.M. Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. Immunol. Res. 31 (2005) 165-176
47. 106-126 is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J. Immunol. 166 (2001) 1448-1451
48. Ying G., Iribarren P., Zhou Y., Gong W., Zhang N., Yu Z.X., Le Y., Cui Y., and Wang J.M. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. 172 (2004) 7078-7085
49. Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., and Reed J.C. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423 (2003) 456-461
50. De Y., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Woosters J., and Oppenheim J.J. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human blood neutrophils, monocytes, and T cells. J. Exp. Med. 192 (2000) 1069-1074
51. Sun R., Iribarren P., Zhang N., Zhou Y., Gong W., Cho E.H., Lockett S., Chertov O., Bednar F., Rogers T.J., Oppenheim J.J., and Wang J.M. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J. Immunol. 173 (2004) 428-436
52. Walther A., Riehemann K., and Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol. Cell 5 (2000) 831-840
53. Hayhoe R.P., Kamal A.M., Solito E., Flower R.J., Cooper D., and Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 107 (2006) 2123-2130
54. Karlsson J., Fu H., Boulay F., Dahlgren C., Hellstrand K., and Movitz C. Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors. J. Leukoc. Biol. 78 (2005) 762-771
55. Kim Y., Lee B.D., Kim O., Bae Y.S., Lee T., Suh P.G., and Ryu S.H. Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1. J. Immunol. 176 (2006) 2969-2975
56. Gao J.L., Lee E.J., and Murphy P.M. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189 (1999) 657-662
57. Boulay F., Mery L., Tardif M., Brouchon L., and Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30 (1991) 2993-2999
58. Gerard N.P., and Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 349 (1991) 614-617
59. Gerard C., and Gerard N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12 (1994) 775-808
60. Marceau F., Bachvarova M., Bergeron J., and Bachvarov D.R. Characterization of a polymorphism in the coding region of the human C5a anaphylatoxin receptor. Immunogenetics 49 (1999) 618-619
61. Barnes K.C., Caraballo L., Munoz M., Zambelli-Weiner A., Ehrlich E., Burki M., Jimenez S., Mathias R.A., Stockton M.L., Deindl P., Mendoza L., Hershey G.K., Nickel R., and Wills-Karp M. A novel promoter polymorphism in the gene encoding complement component 5 receptor 1 on chromosome 19q13.3 is not associated with asthma and atopy in three independent populations. Clin. Exp. Allergy 34 (2004) 736-744
62. Kolakowski L.F., Lu B., Gerard C., and Gerard N. Probing the "message:address" sites for chemoattractant binding to the C5a receptor. J. Biol. Chem. 270 (1995) 18077-18082
63. Höpken U.E., Lu B., Gerard N.P., and Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383 (1996) 86-89
64. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., and Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
65. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Friedl H.P., and Ward P.A. Protective effects of C5a blockade in sepsis. Nat. Med. 5 (1999) 788-792
66. Guo R.-F., and Ward P.A. C5a, a therapeutic target in sepsis. Recent Patents on Anti-Infective Drug Discovery 1 (2006) 57-65
67. Mohr M., Hopken U., Oppermann M., Mathes C., Goldmann K., Siever S., Gotze O., and Burchardi H. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur. J. Clin. Invest. 28 (1998) 227-234
68. Niederbichler A.D., Hoesel L.M., Westfall M.V., Gao H., Ipaktchi K.R., Sun L., Zetoune F.S., Su G.L., Arbabi S., Sarma J.V., Wang S.C., Hemmila M.R., and Ward P.A. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J. Exp. Med. 203 (2006) 53-61
69. Hoesel L.M., Niederbichler A.D., and Ward P.A. Complement-related molecular events in sepsis leading to heart failure. Mol. Immunol. 44 (2007) 95-102
70. Ohno M., Hirata T., Enomoto M., Araki T., Ishimaru H., and Takahashi T.A. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 37 (2000) 407-412
71. Gavrilyuk V., Kalinin S., Hilbush B.S., Middlecamp A., McGuire S., Pelligrino D., Weinberg G., and Feinstein D.L. Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J. Neurochem. 92 (2005) 1140-1149
72. Cain S.A., and Monk P.N. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277 (2002) 7165-7169
73. Okinaga S., Slattery D., Humbles A., Zsengeller Z., Morteau O., Kinrade M.B., Brodbeck R.M., Krause J.E., Choe H.R., Gerard N.P., and Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry 42 (2003) 9406-9415
74. Gerard N.P., Lu B., Liu P., Craig S., Fujiwara Y., Okinaga S., and Gerard C. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280 (2005) 39677-39680
75. Konteatis Z.D., Siciliano S.J., Van-Riper G., Molineaux C.J., Pandya S., Fischer P., Rosen H., Mumford R.A., and Springer M.S. Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 153 (1994) 4200-4205
76. Paczkowski N.J., Finch A.M., Whitmore J.B., Short A.J., Wong A.K., Monk P.N., Cain S.A., Fairlie D.P., and Taylor S.M. Pharmacological characterization of antagonists of the C5a receptor. Br. J. Pharmacol. 128 (1999) 1461-1466
77. Haas P.J., de Haas C.J., Poppelier M.J., van Kessel K.P., van Strijp J.A., Dijkstra K., Scheek R.M., Fan H., Kruijtzer J.A., Liskamp R.M., and Kemmink J. The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J. Mol. Biol. 353 (2005) 859-872
78. Yang D., Chen Q., Stoll S., Chen X., Howard O.M., and Oppenheim J.J. Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: correlation with receptor expression. J. Immunol. 165 (2000) 2694-2702
79. Yang D., Chen Q., Gertz B., He R., Phulsuksombati M., Ye R.D., and Oppenheim J.J. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J. Leukoc. Biol. 72 (2002) 598-607
80. Yang D., Chen Q., Le Y., Wang J.M., and Oppenheim J.J. Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J. Immunol. 166 (2001) 4092-4098
81. Gasque P., Chan P., Fontaine M., Ischenko A., Lamacz M., Götze O., and Morgan B.P. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J. Immunol. 155 (1995) 4882-4889
82. Lacy M., Jones J., Whittemore S.R., Haviland D.L., Wetsel R.A., and Barnum S.R. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J. Neuroimmunol. 61 (1995) 71-78
83. Benard M., Gonzalez B.J., Schouft M.T., Falluel-Morel A., Vaudry D., Chan P., Vaudry H., and Fontaine M. Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J. Biol. Chem. 279 (2004) 43487-43496
84. Laudes I.J., Chu J.C., Huber-Lang M., Guo R.F., Riedemann N.C., Sarma J.V., Mahdi F., Murphy H.S., Speyer C., Lu K.T., Lambris J.D., Zetoune F.S., and Ward P.A. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169 (2002) 5962-5970
85. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., and Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17 (2003) 1003-1014
86. Schraufstatter I.U., Trieu K., Sikora L., Sriramarao P., and DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J. Immunol. 169 (2002) 2102-2110
87. Haviland D.L., McCoy R.L., Whitehead W.T., Akama H., Molmenti E.P., Brown A., Haviland J.C., Parks W.C., Perlmutter D.H., and Wetsel R.A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154 (1995) 1861-1869
88. Riedemann N.C., Guo R.F., Sarma V.J., Laudes I.J., Huber-Lang M., Warner R.L., Albrecht E.A., Speyer C.L., and Ward P.A. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168 (2002) 1919-1925
89. Daveau M., Benard M., Scotte M., Schouft M.T., Hiron M., Francois A., Salier J.P., and Fontaine M. Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J. Immunol. 173 (2004) 3418-3424
90. Riedemann N.C., Guo R.F., Neff T.A., Laudes I.J., Keller K.A., Sarma V.J., Markiewski M.M., Mastellos D., Strey C.W., Pierson C.L., Lambris J.D., Zetoune F.S., and Ward P.A. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110 (2002) 101-118
91. Lee D.K., George S.R., Cheng R., Nguyen T., Liu Y., Brown M., Lynch K.R., and O'Dowd B.F. Identification of four novel human G protein-coupled receptors expressed in the brain. Brain Res. Mol. Brain Res. 86 (2001) 13-22
92. Bokoch G.M. Chemoattractant signaling and leukocyte activation. Blood 86 (1995) 1649-1660
93. Gierschik P., Sidoropoulos D., and Jakobs K.H. Two distinct Gi-proteins mediate formyl peptide receptor signal transduction in human leukemia (HL-60) cells. J. Biol. Chem. 264 (1989) 21470-21473
94. Tsu R.C., Lai H.W., Allen R.A., and Wong Y.H. Differential coupling of the formyl peptide receptor to adenylate cyclase and phospholipase C by the pertussis toxin-insensitive Gz protein. Biochem. J. 309 (1995) 331-339
95. Amatruda T.D., Gerard N.P., Gerard C., and Simon M.I. Specific interactions of chemoattractant factor receptors with G-proteins. J. Biol. Chem. 268 (1993) 10139-10144
96. Bommakanti R.K., Dratz E.A., Siemsen D.W., and Jesaitis A.J. Extensive contact between Gi2 and N-formyl peptide receptor of human neutrophils: mapping of binding sites using receptor-mimetic peptides. Biochemistry 34 (1995) 6720-6728
97. Prossnitz E.R., Quehenberger O., Cochrane C.G., and Ye R.D. The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling. Biochem. J. 294 (1993) 581-587
98. Prossnitz E.R., Schreiber R.E., Bokoch G.M., and Ye R.D. Binding of low affinity N-formyl peptide receptors to G protein. Characterization of a novel inactive receptor intermediate. J. Biol. Chem. 270 (1995) 10686-10694
99. Schreiber R.E., Prossnitz E.R., Ye R.D., Cochrane C.G., and Bokoch G.M. Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling. J. Biol. Chem. 269 (1994) 326-331
100. Matsumoto M.L., Narzinski K., Kiser P.D., Nikiforovich G.V., and Baranski T.J. A comprehensive structure-function map of the intracellular surface of the human C5a receptor: I. Identification of critical residues. J. Biol. Chem. 282 (2007) 3105-3121
101. Matsumoto M.L., Narzinski K., Nikiforovich G.V., and Baranski T.J. A comprehensive structure-function map of the intracellular surface of the human C5a receptor: II. Elucidation of g protein specificity determinants. J. Biol. Chem. 282 (2007) 3122-3133
102. Camps M., Carozzi A., Schnabel P., Scheer A., Parker P.J., and Gierschik P. Isozyme-selective stimulation of phospholipase C-b2 by G protein bg-subunits. Nature 360 (1992) 684-689
103. Stoyanov B., Volinia S., Hanck T., Rubio I., Loubtchenkov M., Malek D., Stoyanova S., Vanhaesebroeck B., Dhand R., Nürnberg B., Gierschik P., Seedorf K., Hsuan J.J., Waterfield M.D., and Wetzker R. Cloning and characterization of a G protein-activated human phoshoinositide-3 kinase. Science 269 (1995) 690-693
104. Hannigan M., Zhan L., Li Z., Ai Y., Wu D., and Huang C.K. Neutrophils lacking phosphoinositide 3-kinase gamma show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3603-3608
105. Hannigan M.O., Huang C.K., and Wu D.Q. Roles of PI3K in neutrophil function. Curr. Top. Microbiol. Immunol. 282 (2004) 165-175
106. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., Sozzani S., Mantovani A., Altruda F., and Wymann M.P. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287 (2000) 1049-1053
107. Tardif M., Rabiet M.-J., Christophe T., Milcent D., and Boulay F. Isolation and characterization of a variant HL60 cell line defective in the activation of the NADPH oxidase by phorbol myristate acetate. J. Immunol. 161 (1998) 6885-6895
108. Tsao L.-T., and Wang J.-P. Translocation of protein kinase C isoforms in rat neutrophils. Biochem. Biophys. Res. Commun. 234 (1997) 412-418
109. Fontayne A., Dang P.M., Gougerot-Pocidalo M.A., and El-Benna J. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 41 (2002) 7743-7750
110. Dekker L.V., Leitges M., Altschuler G., Mistry N., McDermott A., Roes J., and Segal A.W. Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. Biochem. J. 347 Pt 1 (2000) 285-289
111. von Knethen A., Tautenhahn A., Link H., Lindemann D., and Brune B. Activation-induced depletion of protein kinase C alpha provokes desensitization of monocytes/macrophages in sepsis. J. Immunol. 174 (2005) 4960-4965
112. He R., Nanamori M., Sang H., Yin H., Dinauer M.C., and Ye R.D. Reconstitution of chemotactic peptide-induced nicotinamide adenine dinucleotide phosphate (reduced) oxidase activation in transgenic COS-phox cells. J. Immunol. 173 (2004) 7462-7470
113. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S., and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase g. Science 275 (1997) 394-397
114. Rane M.J., Carrithers S.L., Arthur J.M., Klein J.B., and McLeish K.R. Formyl peptide receptor are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways. J. Immunol. 159 (1997) 5070-5078
115. Torres M., Hall F.L., and O'Neill K. Stimulation of human neutrophils with formyl-methionyl-leucyl-phenylalanine induces tyrosine phosphorylation and activation of distinct mitogen-activated protein-kinases. J. Immunol. 150 (1993) 1563-1578
116. Ma Y.C., Huang J., Ali S., Lowry W., and Huang X.Y. Src tyrosine kinase is a novel direct effector of G proteins. Cell 102 (2000) 635-646
117. 2 is phosphorylated and activated by MAP kinase. Cell 72 (1993) 269-278
118. 2 for activation of the phagocyte NADPH oxidase. J. Biol. Chem. 273 (1998) 441-445
119. Rubin B.B., Downey G.P., Koh A., Degousee N., Ghomashchi F., Nallan L., Stefanski E., Harkin D.W., Sun C., Smart B.P., Lindsay T.F., Cherepanov V., Vachon E., Kelvin D., Sadilek M., Brown G.E., Yaffe M.B., Plumb J., Grinstein S., Glogauer M., and Gelb M.H. Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity. J. Biol. Chem. 280 (2005) 7519-7529
120. Kim C., Marchal C.C., Penninger J., and Dinauer M.C. The hemopoietic Rho/Rac guanine nucleotide exchange factor Vav1 regulates N-formyl-methionyl-leucyl-phenylalanine-activated neutrophil functions. J. Immunol. 171 (2003) 4425-4430
121. Welch H.C., Coadwell W.J., Ellson C.D., Ferguson G.J., Andrews S.R., Erdjument-Bromage H., Tempst P., Hawkins P.T., and Stephens L.R. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108 (2002) 809-821
122. Sanchez-Madrid F., and del Pozo M.A. Leukocyte polarization in cell migration and immune interactions. EMBO J. 18 (1999) 501-511
123. Dinauer M.C. Regulation of neutrophil function by Rac GTPases. Curr. Opin. Hematol. 10 (2003) 8-15
124. Symons M., Derry J.M., Karlak B., Jiang S., Lemahieu V., McCormick F., Francke U., and Abo A. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 84 (1996) 723-734
125. Machesky L.M., and Gould K.L. The Arp2/3 complex: a multifunctional actin organizer. Curr. Opin. Cell Biol. 11 (1999) 117-121
126. Tardif M., Brouchon L., Rabiet M.J., and Boulay F. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor. Biochem. J. 372 (2003) 453-463
127. Boxio R., Bossenmeyer-Pourie C., Vanderesse R., Dournon C., and Nusse O. The immunostimulatory peptide WKYMVm-NH activates bone marrow mouse neutrophils via multiple signal transduction pathways. Scand. J. Immunol. 62 (2005) 140-147
128. Partida-Sanchez S., Cockayne D.A., Monard S., Jacobson E.L., Oppenheimer N., Garvy B., Kusser K., Goodrich S., Howard M., Harmsen A., Randall T.D., and Lund F.E. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7 (2001) 1209-1216
129. Partida-Sanchez S., Iribarren P., Moreno-Garcia M.E., Gao J.L., Murphy P.M., Oppenheimer N., Wang J.M., and Lund F.E. Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J. Immunol. 172 (2004) 1896-1906
130. Guse A.H., da Silva C.P., Berg I., Skapenko A.L., Weber K., Heyer P., Hohenegger M., Ashamu G.A., Schulze-Koops H., Potter B.V., and Mayr G.W. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 398 (1999) 70-73
131. Lee H.C. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 317-345
132. Karlsson J., Fu H., Boulay F., Bylund J., and Dahlgren C. The peptide Trp-Lys-Tyr-Met-Val-d-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists. Biochem. Pharmacol. 71 (2006) 1488-1496
133. Bae Y.S., Yi H.J., Lee H.Y., Jo E.J., Kim J.I., Lee T.G., Ye R.D., Kwak J.Y., and Ryu S.H. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J. Immunol. 171 (2003) 6807-6813
134. Lee H.Y., Jo S.H., Lee C., Baek S.H., and Bae Y.S. Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem. Pharmacol. 72 (2006) 860-868
135. Lee H.Y., Kim M.K., Park K.S., Shin E.H., Jo S.H., Kim S.D., Jo E.J., Lee Y.N., Lee C., Baek S.H., and Bae Y.S. Serum amyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Mol. Pharmacol. 70 (2006) 241-248
136. Palanche T., Ilien B., Zoffmann S., Reck M.P., Bucher B., Edelstein S.J., and Galzi J.L. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276 (2001) 34853-34861
137. Kenakin T. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1 (2002) 103-110
138. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 349-379
139. 2+ mobilization. J. Immunol. 157 (1996) 2149-2154
140. Maddox J.F., Hachicha M., Takano T., Petasis N.A., Fokin V.V., and Sherhan C.N. Lipoxin A4 stable analogs are potent mimetics that
141. Farkas I., Baranyi L., Liposits Z.S., Yamamoto T., and Okada H. Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience 86 (1998) 903-911
142. Farkas I., Takahashi M., Fukuda A., Yamamoto N., Akatsu H., Baranyi L., Tateyama H., Yamamoto T., Okada N., and Okada H. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J. Immunol. 170 (2003) 5764-5771
143. Mukherjee P., and Pasinetti G.M. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J. Neuroimmunol. 105 (2000) 124-130
144. Mukherjee P., and Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77 (2001) 43-49
145. Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell. Signal. 16 (2004) 175-186
146. Park P.S., Filipek S., Wells J.W., and Palczewski K. Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry 43 (2004) 15643-15656
147. Lee S.P., O'Dowd B.F., and George S.R. Homo- and hetero-oligomerization of G protein-coupled receptors. Life Sci. 74 (2003) 173-180
148. Angers S., Salahpour A., and Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 409-435
149. Floyd D.H., Geva A., Bruinsma S.P., Overton M.C., Blumer K.J., and Baranski T.J. C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. J. Biol. Chem. 278 (2003) 35354-35361
150. Gripentrog J.M., Kantele K.P., Jesaitis A.J., and Miettinen H.M. Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171 (2003) 3187-3193
151. Milligan G. Oligomerisation of G-protein-coupled receptors. J. Cell Sci. 114 (2001) 1265-1271
152. Springael J.Y., Urizar E., and Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 16 (2005) 611-623
153. Klco J.M., Lassere T.B., and Baranski T.J. C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J. Biol. Chem. 278 (2003) 35345-35353
154. Geva A., Lassere T.B., Lichtarge O., Pollitt S.K., and Baranski T.J. Genetic mapping of the human C5a receptor. Identification of transmembrane amino acids critical for receptor function. J. Biol. Chem. 275 (2000) 35393-35401
155. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Annu. Rev. Biochem. 67 (1998) 653-692
156. Ali H., Richardson R.M., Haribabu B., and Snyderman R. Chemoattractant receptor cross-desensitization. J. Biol. Chem. 274 (1999) 6027-6030
157. Huttenrauch F., Pollok-Kopp B., and Oppermann M. G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J. Biol. Chem. 280 (2005) 37503-37515
158. Shen W., Li B., Wetzel M.A., Rogers T.J., Henderson E.E., Su S.B., Gong W., Le Y., Sargeant R., Dimitrov D.S., Oppenheim J.J., and Wang J.M. Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood 96 (2000) 2887-2894
159. Li B.Q., Wetzel M.A., Mikovits J.A., Henderson E.E., Rogers T.J., Gong W., Le Y., Ruscetti F.W., and Wang J.M. The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood 97 (2001) 2941-2947
160. Gomez-Mouton C., Lacalle R.A., Mira E., Jimenez-Baranda S., Barber D.F., Carrera A.C., Martinez A.C., and Manes S. Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis. J. Cell Biol. 164 (2004) 759-768
161. Servant G., Weiner O.D., Neptune E.R., Sedat J.W., and Bourne H.R. Dynamics of a chemoattractant receptor in living neutrophils during chemotaxis. Mol. Biol. Cell 10 (1999) 1163-1178
162. Xue M., Vines C.M., Buranda T., Cimino D.F., Bennett T.A., and Prossnitz E.R. N-formyl peptide receptors cluster in an active Raft-associated state prior to phosphorylation. J. Biol. Chem. 279 (2004) 45175-45184
163. Bennett T.A., Foutz T.D., Gurevich V.V., Sklar L.A., and Prossnitz E.R. Partial phosphorylation of the N-formyl peptide receptor inhibits G protein association independent of arrestin binding. J. Biol. Chem. 276 (2001) 49195-49203
164. Jesaitis A.J., and Klotz K.N. Cytoskeletal regulation of chemotactic receptors: molecular complexation of N-formyl peptide receptors with G proteins and actin. Eur. J. Haematol. 51 (1993) 288-293
165. Bylund J., Bjorstad A., Granfeldt D., Karlsson A., Woschnagg C., and Dahlgren C. Reactivation of formyl peptide receptors triggers the neutrophil NADPH-oxidase but not a transient rise in intracellular calcium. J. Biol. Chem. 278 (2003) 30578-30586
166. Tardif M., Mery L., Brouchon L., and Boulay F. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells. J. Immunol. 150 (1993) 3534-3545
167. Ali H., Richardson R.M., Tomhave E.D., Didsbury J.R., and Snyderman R. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlate with differences in desensitization. J. Biol. Chem. 268 (1993) 24247-24254
168. Giannini E., and Boulay F. Phosphorylation, dephosphorylation, and recycling of the C5a receptor in differentiated HL60 cells. J. Immunol. 154 (1995) 4055-4064
169. Giannini E., Brouchon L., and Boulay F. Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo. J. Biol. Chem. 270 (1995) 19166-19172
170. Langkabel P., Zwirner J., and Oppermann M. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by G protein-coupled receptor kinases. Eur. J. Immunol. 29 (1999) 3035-3046
171. Milcent M.D., Christophe T., Rabiet M.-J., Tardif M., and Boulay F. Overexpression of wild-type and catalytically inactive forms of GRK2 and GRK6 fails to alter the agonist-induced phosphorylation of the C5a receptor (CD88): evidence that GRK6 is autophosphorylated in COS-7 cells. Biochem. Biophys. Res. Commun. 259 (1999) 224-229
172. Christophe T., Rabiet M.-J., Tardif M., Milcent M.-D., and Boulay F. Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses. J. Biol. Chem. 275 (2000) 1656-1664
173. Naik N., Giannini E., Brouchon L., and Boulay F. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell Sci. 110 (1997) 2381-2390
174. Braun L., Christophe T., and Boulay F. Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-dependent pathway. J. Biol. Chem. 278 (2003) 4277-4285
175. Prossnitz E.R., Kim C.M., Benovic J.L., and Ye R.D. Phosphorylation of the N-formyl peptide receptor carboxyl terminus by the G protein-coupled receptor kinase, GRK2. J. Biol. Chem. 270 (1995) 1130-1137
176. Maestes D.C., Potter R.M., and Prossnitz E.R. Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor. J. Biol. Chem. 274 (1999) 29791-29795
177. Onorato J.J., Palczewski K., Regan J.W., Caron M.G., Lefkowitz R.J., and Benovic J.L. Role of acidic amino acids in peptide substrates of the b-adrenergic receptor kinase and rhodopsin kinase. Biochemistry 30 (1991) 5118-5125
178. Potter R.M., Maestas D.C., Cimino D.F., and Prossnitz E.R. Regulation of N-formyl peptide receptor signaling and trafficking by individual carboxyl-terminal serine and threonine residues. J. Immunol. 176 (2006) 5418-5425
179. Key T.A., Foutz T.D., Gurevich V.V., Sklar L.A., and Prossnitz E.R. N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity. J. Biol. Chem. 278 (2003) 4041-4047
180. Key T.A., Vines C.M., Wagener B.M., Gurevich V., Sklar L.A., and Prossnitz E. Inhibition of chemoattractant N-formyl peptide receptor trafficking by active arrestins. Traffic 6 (2005) 1-13
181. Han M., Gurevich V.V., Vishnivetskiy S.A., Sigler P.B., and Schubert C. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane translocation. Structure (Camb.) 9 (2001) 869-880
182. Milano S.K., Pace H.C., Kim Y.M., Brenner C., and Benovic J.L. Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 41 (2002) 3321-3328
183. Goodman O.B., Krupnick J.G.J., Santini F., Gurevich V.V., Penn R.B., Gagnon A.W., Keen J.H., and Benovic J.L. b-Arrestin acts as a clathrin adaptor in endocytosis of the b2-adrenergic receptor. Nature 383 (1996) 447-450
184. Laporte S.A., Oakley R.H., Holt J.A., Barak L.S., and Caron M.G. The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J. Biol. Chem. 275 (2000) 23120-23126
185. Scott M.G., Benmerah A., Muntaner O., and Marullo S. Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells. J. Biol. Chem. 277 (2002) 3552-3559
186. Damke H. Dynamin and receptor-mediated endocytosis. FEBS Lett. 389 (1996) 48-51
187. McLaughlin N.J., Banerjee A., Kelher M.R., Gamboni-Robertson F., Hamiel C., Sheppard F.R., Moore E.E., and Silliman C.C. Platelet-activating factor-induced clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation. J. Immunol. 176 (2006) 7039-7050
188. Gilbert T.L., Bennett T.A., Maestas D.C., Cimino D.F., and Prossnitz E.R. Internalization of the human N-formyl peptide and C5a chemoattractant receptors occurs via clathrin-independent mechanisms. Biochemistry 40 (2001) 3467-3475
189. Vines C.M., Revankar C.M., Maestas D.C., LaRusch L.L., Cimino D.F., Kohout T.A., Lefkowitz R.J., and Prossnitz E.R. N-formyl peptide receptors internalize but do not recycle in the absence of arrestins. J. Biol. Chem. 278 (2003) 41581-41584
190. Kohout T.A., Lin F.S., Perry S.J., Conner D.A., and Lefkowitz R.J. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1601-1606
191. Ernst S., Zobiack N., Boecker K., Gerke V., and Rescher U. Agonist-induced trafficking of the low-affinity formyl peptide receptor FPRL1. Cell. Mol. Life Sci. 61 (2004) 1684-1692
192. Lefkowitz R.J., and Whalen E.J. beta-Arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol. 16 (2004) 162-168
193. Shenoy S.K., and Lefkowitz R.J. Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J. Biol. Chem. 280 (2005) 15315-15324
194. Suvorova E.S., Gripentrog J.M., and Miettinen H.M. Different endocytosis pathways of the C5a receptor and the N-formyl peptide receptor. Traffic 6 (2005) 100-115
195. Shenoy S.K., McDonald P.H., Kohout T.A., and Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294 (2001) 1307-1313
196. Wang Y., Zhou Y., Szabo K., Haft C.R., and Trejo J. Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1. Mol. Biol. Cell 13 (2002) 1965-1976
197. Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P., Murray S.R., and Von Zastrow M. Modulation of postendocytic sorting of G protein-coupled receptors. Science 297 (2002) 615-620
198. Zhou Y., Bian X., Le Y., Gong W., Hu J., Zhang X., Wang L., Iribarren P., Salcedo R., Howard O.M., Farrar W., and Wang J.M. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J. Natl. Cancer Inst. 97 (2005) 823-835
199. McCoy R., Haviland D.L., Molmenti E.P., Ziambaras T., Wetsel R.A., and Perlmutter D.H. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J. Exp. Med. 182 (1995) 207-217
200. Anton P., O'Connell J., O'Connell D., Whitaker L., O'Sullivan G.C., Collins J.K., and Shanahan F. Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylanine (FMLP). Gut 42 (1998) 374-379
201. Becker E.L., Forouhar F.A., Grunnet M.L., Boulay F., Tardif M., Bormann B.-J., Sodja D., Ye R.D., Woska Jr. J.R., and Murphy P.M. Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells. Cell Tissue Res. 292 (1998) 129-135
202. Gronert K., Gewirtz A., Madara J.L., and Serhan C.N. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon g and inhibits tumor necrosis factor a-induced IL-8 release. J. Exp. Med. 187 (1998) 1285-1294
203. Keitoku M., Kohzuki M., Katoh H., Funakoshi M., Suzuki S., Takeuchi M., Karbe A., Horiguchi S., Watanabe J., Satoh S., Nose M., Abe K., Okayama H., and Shirato K. FMLP actions and its binding sites in isolated human coronary arteries. J. Mol. Cell. Cardiol. 29 (1997) 881-894
204. Le Y., Hu J., Gong W., Shen W., Li B., Dunlop N.M., Halverson D.O., Blair D.G., and Wang J.M. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J. Neuroimmunol. 111 (2000) 102-108
205. Floreani A.A., Heires A.J., Welniak L.A., Miller-Lindholm A., Clark-Pierce L., Rennard S.I., Morgan E.L., and Sanderson S.D. Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J. Immunol. 160 (1998) 5073-5081
206. Van Beek J., Bernaudin M., Petit E., Gasque P., Nouvelot A., MacKenzie E.T., and Fontaine M. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp. Neurol. 161 (2000) 373-382
207. E. Huet, M.-J. Rabiet, S. Barral, F. Boulay, The role of beta-arrestins in the formyl peptide receptor-like 1 internalization and signaling, submitted for publication.
208. Gripentrog J.M., and Miettinen H.M. Activation and nuclear translocation of ERK1/2 by the formyl peptide receptor is regulated by G protein and is not dependent on beta-arrestin translocation or receptor endocytosis. Cell Signal 17 (2005) 1300-1311